[Asia Economy Reporter Eunbyeol Kim] Pfizer of the United States and BioNTech of Germany, who are jointly developing a novel coronavirus infection (COVID-19) vaccine, announced on the 9th (local time) that "analysis of the COVID-19 vaccine's effectiveness proved an efficacy of over 90%."
According to the Wall Street Journal (WSJ) and others, the two companies stated that analysis conducted on 94 patients exhibiting one or more COVID-19 symptoms demonstrated an efficacy of over 90%.
They also said, "No serious safety issues were observed in the Phase 3 clinical trial results," and added, "If the vaccine is deemed safe, we plan to request authorization to sell the vaccine to health authorities before the end of this month."
Pfizer's stock price is surging about 7% in the pre-market trading.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
